Immunoregulatory Impact of miR-124 and miR-223 on Some Immunological Parameters in Rheumatoid Arthritis
DOI:
https://doi.org/10.37134/jsml.vol13.2.1.2025Keywords:
Immunoregulation, MicroRNAs, Pro-inflammatory cytokines, sCD28Abstract
Rheumatoid arthritis (RA) is a long-lasting autoimmune disorder that causes inflammation of the synovium and the destruction of joints. This study evaluated the expression of miR-124 and miR-223 in RA patients and their association with key inflammatory markers: sCD28, IL-6, IL-17A, IL-40, MCP-1, and VEGF. One hundred eighty participants were enrolled, including 120 RA patients (newly diagnosed and biologically treated) and 60 healthy controls. Serum cytokine levels were measured using sandwich ELISA, and miRNA expression was quantified by qRT-PCR. Results revealed significant, distinct yet overlapping dysregulation of miR-124 and miR-223 in RA patients in comparison to controls, influenced by inflammatory status, therapeutic intervention, and patient-specific factors. These alterations correlated positively with raised serum levels of IL-6, IL-17A, and VEGF, indicating active inflammation, immune activation, and angiogenesis. Biological therapy significantly reduced miRNA dysregulation and inflammatory marker levels, reflecting effective disease control. The expression profiles of miR-124 and miR-223 closely reflected both inflammatory activity and therapeutic response. The correlation between expression of miR-223 and pro-inflammatory mediators reinforce its role in supporting T-cell activation and immunogenic signaling, while the contrary pattern of miR-124 indicates a regulatory role in modulating inflammatory cascades and angiogenesis. The immunological indicators sCD28, MCP-1, IL-40, and VEGF illuminate the reciprocal influence of immune activation, chemotaxis, and vascular remodeling in the pathogenesis of RA. The study's outcomes substantiate miR-124 and miR-223 as consistent diagnostic biomarkers of RA. Moreover, the essential roles of related immunological markers in disease activity and therapeutic response. This study contributes to enhancing the importance of using miRNA in modifying the immune reaction by influencing the concentration and function of inflammatory mediators to reduce the development and severity of RA and enhances the therapeutic response, with the feasibility of using them as diagnostic parameters and therapeutic targets.
Downloads
References
Abed RM, Abdulmalek HW, Yaaqoob LA, Altaee MF, Kamona ZK. (2023). Serum level and genetic polymorphism of IL-38 and IL-40 in autoimmune thyroid disease. Iraqi Journal of Science, 2786-2797. doi:10.24996/ijs.2023.64.6.12
AlChalabi R, Jaafer RS, Mahmood RI, Al-Rahim AM, Omer D. (2024). Role of several cytokines and vitamin D deficiency in the progression of rheumatoid arthritis in Iraqi patients. Epitheorese Klinikes Farmakologias Kai Farmakokinetikes, 42(1), 9-15. doi:10.61873/UTDA8218
Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Ménard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsky J, Wolfe F, Hawker G. (2010). 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Annals of the Rheumatic Diseases, 69(9), 1580-1588. doi:10.1136/ard.2010.138461
Alivernini S, Masserdotti A, Magatti M, Cargnoni A, Papait A, Silini AR, Parolini O. (2025). Exploring perinatal mesenchymal stromal cells as a potential therapeutic strategy for rheumatoid arthritis. Heliyon, 11(1), e41438. doi:10.1016/j.heliyon.2024.e41438
Al-Rahim AM, AlChalabi R, Al-Saffar AZ, Sulaiman GM, Albukhaty S, Belali T, Khalil KA. (2023). Folate-methotrexate loaded bovine serum albumin nanoparticles preparation: An in vitro drug targeting cytokines overwhelming expressed immune cells from rheumatoid arthritis patients. Animal Biotechnology, 34(2), 166-182. doi:10.1080/10495398.2021.1951282
Aziz F. (2016). The emerging role of miR-223 as novel potential diagnostic and therapeutic target for inflammatory disorders. Cellular immunology, 303, 1-6. doi:10.1016/j.cellimm.2016.04.003
Chen JQ, Papp G, Szodoray P, Zeher M. (2014). The role of microRNAs in the pathogenesis of autoimmune diseases. Autoimmunity Reviews, 15(12), 1171-1180. doi:10.1016/j.autrev.2016.09.003
Cui S, Qian J. (2023). Future biomarkers for infection and inflammation in rheumatoid arthritis. Journal of Inflammation Research, 16, 2719-2726. doi:10.2147/JIR.S413579
Cutolo M, Paolino S, Smith V. (2014). Vitamin D steroid hormones, and autoimmunity. Annals of the New York Academy of Sciences, 1317(1), 39-46. doi:10.1111/nyas.12432
Dabbagh-Gorjani F. (2024). A comprehensive review on the role of interleukin‐40 as a biomarker for diagnosing inflammatory diseases. Autoimmune Diseases, 1, 3968767. doi:10.1155/2024/3968767
Daien C, Krogulec M, Gineste P, Steens JM, Du Roure LD, Biguenet S, Durez P. (2022). Safety and efficacy of the miR-124 upregulator ABX464 (obefazimod, 50 and 100 mg per day) in patients with active rheumatoid arthritis and inadequate response to methotrexate and/or anti-TNFα therapy: A placebo-controlled phase II study. Annals of the Rheumatic Diseases, 81(8), 1076-1084. doi:10.1136/annrheumdis-2022-222228
Dammacco R, Guerriero S, Alessio G, Dammacco F. (2022). Natural and iatrogenic ocular manifestations of rheumatoid arthritis: a systematic review. International Ophthalmology, 42(2), 689-711. doi:10.1007/s10792-021-02058-8
Das K, Rao LVM. (2022). The role of microRNAs in inflammation. International Journal of Molecular Sciences, 23(24), 15479. doi:10.3390/ijms232415479
Ding Q, Hu W, Wang R, Yang Q, Zhu M, Li M, Zhu YZ. (2023). Signaling pathways in rheumatoid arthritis: implications for targeted therapy. Signal Transduction and Targeted Therapy, 8(1), 68. doi:10.1038/s41392-023-01331-9
Edner NM, Carlesso G, Rush JS, Walker LS. (2020). Targeting co-stimulatory molecules in autoimmune disease. Nature Reviews Drug Discovery, 19(12), 860-883. doi:10.1038/s41573-020-0081-9
El-Din SS, Rashed LA, Eissa M, Eldemery AB, Mohammed OA, Abdelgwad M. (2022). Potential role of circRNA-HIPK3/microRNA-124a crosstalk in the pathogenesis of rheumatoid arthritis. Reports of Biochemistry & Molecular Biology, 10(4), 527. doi:10.52547/rbmb.10.4.527
Emerson D, Merriman E, Yachi PP. (2025). Rheumatoid arthritis-associated cytokines and therapeutics modulate immune checkpoint receptor expression on T cells. Frontiers in Immunology, 16, 1534462. doi:10.3389/fimmu.2025.1534462
Gao Y, Zhang Y, Liu X. (2024). Rheumatoid arthritis: Pathogenesis and therapeutic advances. MedComm, 5(3), e509. doi:10.1002/mco2.509
Haarhaus ML, Klareskog L. (2024). The lung as a target and as an initiator of rheumatoid arthritis-associated immunity: Implications for interstitial lung disease. Revista Colombiana de Reumatología, 31, 74-81. doi:10.1016/j.rcreue.2023.09.002
Hussein HS, Al-Fatlawi IH. (2022). The Role of IL-6 (-174G/C) Polymorphism in the Immunopathogenesis of Rheumatoid Arthritis. Wasit Journal of Pure Science, 15(2), 42-51. doi:10.31185/wjps.50
Jaleel K, Risala H, Yasir W. (2022). Assessment of hematological parameters and immune cell CD markers in Iraqi patients with acute myeloid leukemia. Al-Nahrain Journal of Science, 28(5), 82-90. doi:10.22401/ANJS.28.1.09
Jasim R., Alchalabi, R., Jaafer, R. (2024). The association between body mass index, diagnostic markers and disease activity score with progression of rheumatoid arthritis in a sample of Iraqi patients. Journal of Biotechnology Research Center, 18(1), 5-10. doi:10.24126/jobrc.2024.18.1.708
Jiao P, Wang XP, Luoreng ZM, Yang J, Jia L, Ma Y, Wei DW. (2021). miR-223: An effective regulator of immune cell differentiation and inflammation. International Journal of Biological Sciences, 17(9), 2308-2322. doi:10.7150/ijbs.59876
Khan M, Arooj S, Wang H. (2021). Soluble B7-CD28 family inhibitory immune checkpoint proteins and anti-cancer immunotherapy. Frontiers in Immunology, 12, 651634. doi:10.3389/fimmu.2021.651634
Kondo N, Kuroda T, Kobayashi D. (2021). Cytokine networks in the pathogenesis of rheumatoid arthritis. International Journal of Molecular Sciences, 22(20), 10922. doi:10.3390/ijms222010922
Le T, and Kwon S. (2021). Vascular endothelial growth factor biology and its potential as a therapeutic target in rheumatic diseases. International Journal of Molecular Sciences, 22(10), 5387. doi:10.3390/ijms22105387
Li J, Wan Y, Guo Q, Zou L, Zhang J, Fang Y, Wu Y. (2010). Altered microRNA expression profile with miR-146a upregulation in CD4⁺ T cells from patients with rheumatoid arthritis. Arthritis Research & Therapy, 12, 1-12. doi:10.1186/ar3006
Li X, Shao M, Zeng X, Qian P, Huang H. (2021). Signaling pathways in the regulation of cytokine release syndrome in human diseases and intervention therapy. Signal Transduction and Targeted Therapy, 6(1), 367. doi:10.1038/s41392-021-00815-w
Luo H, Li L, Han S, Liu T. (2024). The role of monocyte/macrophage chemokines in pathogenesis of osteoarthritis: A review. International Journal of Immunogenetics, 51(3), 130-142. doi:10.1111/iji.12664
Mohammed SI, Jasim AL, Jamal MY, Hussain SA. (2023). Factors influencing adalimumab treatment response in patients with rheumatoid arthritis: The future of clinical expertise. Al-Rafidain Journal of Medical Sciences, 5, 192-204. doi:10.54133/ajms.v5i.232
Mumtaz M, Hussain N. (2020). Rheumatoid arthritis and the role of VEGF gene: an overview. Journal of Scientific Research in Medical and Biological Sciences, 1(2), 75-90. doi:10.47631/jsrmbs.v1i2.93
Navrátilová A, Andrés Cerezo L, Hulejová H, Bečvář V, Tomčík M, Komarc M, Šenolt L. (2021). IL-40: a new B cell-associated cytokine up-regulated in rheumatoid arthritis decreases following the rituximab therapy and correlates with disease activity, autoantibodies, and netosis. Frontiers in Immunology, 12, 745523. doi:10.3389/fimmu.2021.745523
Peng X, Wang Q, Li W, Ge G, Peng J, Xu Y, Geng D. (2023). Comprehensive overview of microRNA function in rheumatoid arthritis. Bone Research, 11(1), 8. doi:10.1038/s41413-023-00244-1
Qamar T, Ansari MS, Masihuddin, Mukherjee S. (2025). MicroRNAs as biomarker in rheumatoid arthritis: Pathogenesis to clinical relevance. Journal of Cellular Biochemistry, 126, e30690. doi:10.1002/jcb.30690
Raina P, Sikka R, Gupta H, Matharoo K, Bali SK, Singh V, Bhanwer AJS. (2021). Association of eNOS and MCP-1 genetic variants with type 2 diabetes and diabetic nephropathy susceptibility: A case-control and meta-analysis study. Biochemical Genetics, 59(4), 966-996. doi:10.1007/s10528-021-10041-2
Robert M, Miossec P. (2019). IL-17 in rheumatoid arthritis and precision medicine: from synovitis expression to circulating bioactive levels. Frontiers in Medicine, 5, 364. doi:10.3389/fmed.2018.00364
Sakalyte R, Bagdonaite L, Stropuviene S, Naktinyte S, Venalis A. (2022). VEGF profile in early undifferentiated arthritis cohort. Medicina, 58(6), 833. doi:10.3390/medicina58060833
Selimov P, Karalilova R, Damjanovska L, Delcheva G, Stankova T, Stefanova K, Batalov, A. (2023). Rheumatoid arthritis and the proinflammatory cytokine IL-17. Folia Medica, 65(1), 53-59. doi:10.3897/folmed.65.e72448
Singh JA, Saag KG, Bridges Jr SL, Akl EA, Bannuru RR, Sullivan MC, McAlindon T. (2016). 2015 American College of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis & Rheumatology, 68(1), 1-26. doi:10.1002/art.39480
Smolen JS, Aletaha D, McInnes IB. (2018). Rheumatoid arthritis. The Lancet, 388, 2023-2038. doi:10.1016%2FS0140-6736%2816%2930173-8
Su QY, Zhang JT, Gao HJ, Zhang Y, Luo J, Cao TY, Zhang SX. (2025). Mechanism and clinical utility of abatacept in the treatment of rheumatoid arthritis. Expert Opinion on Drug Safety, 1-12. doi:10.1080/14740338.2025.2505542
Talib AF, Mohammed MM. (2024). Treatment satisfaction and health-related quality of life in Iraqi patients with rheumatoid arthritis receiving biologic therapy; Rituximab. Iraqi Journal of Pharmaceutical Sciences, 33, 230-235. doi:10.31351/vol33iss(4SI)pp230-235
Taylor PC, Feist E, Pope JE, Nash P, Sibilia J, Caporali R, Balsa A. (2024). What have we learnt from the inhibition of IL-6 in RA and what are the clinical opportunities for patient outcomes? Therapeutic Advances in Musculoskeletal Disease, 16, 1-19. doi:10.1177/1759720X241283340
Tong X, Zeng H, Gu P, Wang K, Zhang H, Lin X. (2020). Monocyte chemoattractant protein-1 promotes the proliferation, migration and differentiation potential of fibroblast-like synoviocytes via the PI3K/P38 cellular signaling pathway. Molecular Medicine Reports, 21(3), 1623-1632. doi:10.3892/mmr.2020.10969
Van der Helm-van Mil AHM, Verpoort KN, Breedveld FC, Toes REM, Huizinga TWJ. (2005). Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Research & Therapy, 7(5), 949-958. doi:10.1186/ar1767
Weyand CM, Goronzy JJ. (2021). The immunology of rheumatoid arthritis. Nature Immunology, 22(1), 10-18. doi:10.1038/s41590-020-00816-x
Wu T, Zhang Y, Peng A, Wu X. (2023). The diagnostic value of miR-124a expression in peripheral blood and synovial fluid of patients with rheumatoid arthritis. Human Heredity, 88(1), 58-67. doi:10.1159/000529171
Zamzam YA, Mansour TF, Salem RM, Aziz RSA, Elsendiony SA. (2024). Serum miR-124a and miR-34a as potential biomarkers for rheumatoid arthritis. Biomedical and Biotechnology Research Journal, 8(2), 166-171. doi:10.4103/bbrj.bbrj_142_24
Zhang Y, Yang M, Xie H, Hong F, Yang S. (2023). Role of miRNAs in rheumatoid arthritis therapy. Cells, 12(13), 1749. doi:10.3390/cells12131749
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Aya Sabah Hameed, Rawaa AlChalabi
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
